{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/macular-degeneration-age-related/","result":{"data":{"firstChapter":{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field e2cffa47-7dfb-4837-8c4d-70bace4e5ce5 --><h1>Macular degeneration - age-related: Summary</h1><!-- end field e2cffa47-7dfb-4837-8c4d-70bace4e5ce5 -->","htmlStringContent":"<!-- begin item 09a54df8-1f12-4d38-b90c-a1c4c35d9c61 --><!-- begin field 5b14372c-9efd-4758-9fcd-d43e3ac6696e --><ul><li>Age-related macular degeneration (AMD) is the term applied to changes, without any other obvious precipitating cause, which occur in the central area of the retina (macula) in people aged 50 years and over.</li><li>Changes that occur in AMD include one or more of:<ul><li>Drusen — collections of lipid material that accumulate beneath the retinal pigment epithelium (RPE) and within Bruch’s membrane. </li><li>RPE abnormalities — areas of hypopigmentation or hyperpigmentation. </li><li>Geographic atrophy — breakdown of light-sensitive cells in the macula causes one or more sharply demarcated areas of partial or complete depigmentation (atrophy) of the RPE. The areas of atrophy can enlarge over time and may or may not involve the fovea. </li><li>Neovascular (exudative) AMD — the development of new blood vessels in the choroid. The new vessels are unlike normal vessels and easily bleed or leak blood constituents, resulting in distortion and scarring of the retina.</li></ul></li><li>AMD is classified into:<ul><li>Early AMD — low risk of progression, medium risk of progression, or high risk of progression.</li><li>Late AMD — intermediate, wet active, dry, or wet inactive. </li></ul></li><li>Advanced AMD is the commonest cause of severe visual impairment in older adults in the developed world.</li><li>The cause of AMD is unknown but established risk factors include older age, smoking, a family history of AMD, and genetic factors.</li><li>Complications of AMD include: <ul><li>Visual impairment and blindness. </li><li>Visual hallucinations.</li><li>Depression.</li><li>Falls and fractures.</li><li>Reduced quality of life. </li></ul></li><li>Generally, early and intermediate AMD are not associated with disturbances of central visual function, but advanced AMD can cause severe visual impairment. <ul><li>Geographic atrophy tends to progress slowly.</li><li>Untreated neovascular AMD can progress within weeks or months to cause severe visual loss.</li></ul></li><li>Symptoms of AMD include:<ul><li>Distortion of vision, where straight lines appear crooked or wavy.</li><li>Painless loss, or blurring, of central or near-central vision.</li><li>A black or grey patch affecting the central field of vision (scotoma).</li><li>Difficulty reading, driving, or seeing fine detail (such as facial features). </li><li>Flickering or flashing lights (photopsia). </li><li>Difficulty adjusting from bright to dim lighting.</li><li>Visual hallucinations (associated with severe visual loss). </li></ul></li><li>On examination, visual acuity may be normal or reduced. </li><li>If AMD is suspected, urgent referral to an ophthalmologist should be arranged within a week as treatment for neovascular AMD should be started promptly to preserve sight. </li><li>Management in secondary care includes intraocular injections of anti-angiogenic drugs for neovascular AMD. </li></ul><!-- end field 5b14372c-9efd-4758-9fcd-d43e3ac6696e --><!-- end item 09a54df8-1f12-4d38-b90c-a1c4c35d9c61 -->","topic":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d","topicId":"819a45d3-fd1c-42c7-8420-27d4daf53cc2","topicName":"Macular degeneration - age-related","slug":"macular-degeneration-age-related","aliases":["Age-related macular degeneration"],"chapters":[{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"bb451071-7381-59cb-aa21-2b2bccafe2d2","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"5006d91f-871e-5987-a351-38613676d868","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"b46dda65-9a23-5d6c-9afe-03e05a87cc3c","slug":"changes","fullItemName":"Changes"},{"id":"a82ab674-261f-5a3d-8d12-5c13643cd924","slug":"update","fullItemName":"Update"}]},{"id":"e40fe343-86d1-5303-af86-c3b22d664113","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"807a5294-312b-51b7-8a2b-2b7d9c18a2a2","slug":"goals","fullItemName":"Goals"},{"id":"875cd1b7-ea38-5e4d-b1ac-1c4d4e110927","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1c4bcbde-43f9-57c5-87d2-37e2a7bfc7b3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73e19abc-9ba2-505a-aae8-23b40e76c49f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cb9a7aab-681a-5b78-aca6-dcb97a9ae535","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25a06a16-e897-5cb6-bdf2-99705c2c3f77","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition"},{"id":"e34a411a-f7c0-5084-965b-49ac89736d30","slug":"classification","fullItemName":"Classification"},{"id":"d537f969-c989-57cd-824a-d0718c657988","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4098eb73-c982-50a6-830c-61d7dc25c997","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1313d171-0d54-5814-baef-2c79e54a147e","slug":"complications","fullItemName":"Complications"}]},{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fa4cdf98-731f-5fab-b1b9-802d0ad26a9e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","slug":"management","fullItemName":"Management","subChapters":[{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD"},{"id":"1d91de12-c8ef-5335-9359-81816456fb81","slug":"confirmed-amd","fullItemName":"Scenario: Confirmed AMD"}]},{"id":"0c6673ad-62d1-59a7-93a7-dc791491644d","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"81330a87-dcef-52cd-9707-efa0e22c0435","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"565ac27d-4e4d-5f6c-ba0a-bef0793f4f68","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"97a694f8-29e3-5e9b-9e46-68e52e2499d0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"adea819b-f313-5842-8936-3b1d2feee7ad","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e49d7e10-0bcd-5d89-b7f3-64d4ff858f1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8059070a-a973-530d-8d9b-0e4cb14d5b65","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4ea345d9-fe7e-558f-b710-2bb252185ef8","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d","topicId":"819a45d3-fd1c-42c7-8420-27d4daf53cc2","topicName":"Macular degeneration - age-related","slug":"macular-degeneration-age-related","aliases":["Age-related macular degeneration"],"topicSummary":"Age-related macular degeneration (AMD) is the term applied to changes, which occur in the central area of the retina.","lastRevised":"Last revised in October 2020","nextPlannedReviewBy":"2025-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2025-09","nextPlannedReviewByDisplay":"September 2025","specialities":[{"id":"485bdd1b-4437-5374-838e-f1f1db61a424","name":"Eyes","slug":"eyes"}],"chapters":[{"id":"8dda5709-9896-57f9-9907-7fb9c46fe863","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"bb451071-7381-59cb-aa21-2b2bccafe2d2","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"5006d91f-871e-5987-a351-38613676d868","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"b46dda65-9a23-5d6c-9afe-03e05a87cc3c","slug":"changes","fullItemName":"Changes"},{"id":"a82ab674-261f-5a3d-8d12-5c13643cd924","slug":"update","fullItemName":"Update"}]},{"id":"e40fe343-86d1-5303-af86-c3b22d664113","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"807a5294-312b-51b7-8a2b-2b7d9c18a2a2","slug":"goals","fullItemName":"Goals"},{"id":"875cd1b7-ea38-5e4d-b1ac-1c4d4e110927","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1c4bcbde-43f9-57c5-87d2-37e2a7bfc7b3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"73e19abc-9ba2-505a-aae8-23b40e76c49f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cb9a7aab-681a-5b78-aca6-dcb97a9ae535","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"25a06a16-e897-5cb6-bdf2-99705c2c3f77","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7cb3e392-3b5c-558a-988c-646bacf307bb","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"69a4bcc6-b18d-52c2-b7f8-b74b4bebf32c","slug":"definition","fullItemName":"Definition"},{"id":"e34a411a-f7c0-5084-965b-49ac89736d30","slug":"classification","fullItemName":"Classification"},{"id":"d537f969-c989-57cd-824a-d0718c657988","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4098eb73-c982-50a6-830c-61d7dc25c997","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c49a0066-054e-5666-9b2d-7bad39b079cc","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1313d171-0d54-5814-baef-2c79e54a147e","slug":"complications","fullItemName":"Complications"}]},{"id":"5daaa827-5772-5a33-8675-cf20b916db2e","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"7fd2b2d6-9e86-5014-bc61-f30ce19d5712","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fa4cdf98-731f-5fab-b1b9-802d0ad26a9e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"491fb145-6067-5e5d-b364-2a3d874dcbde","slug":"management","fullItemName":"Management","subChapters":[{"id":"623a85d0-3eef-5b46-a5a6-0c14facafc46","slug":"suspected-amd","fullItemName":"Scenario: Suspected AMD"},{"id":"1d91de12-c8ef-5335-9359-81816456fb81","slug":"confirmed-amd","fullItemName":"Scenario: Confirmed AMD"}]},{"id":"0c6673ad-62d1-59a7-93a7-dc791491644d","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"81330a87-dcef-52cd-9707-efa0e22c0435","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"565ac27d-4e4d-5f6c-ba0a-bef0793f4f68","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"97a694f8-29e3-5e9b-9e46-68e52e2499d0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"adea819b-f313-5842-8936-3b1d2feee7ad","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e49d7e10-0bcd-5d89-b7f3-64d4ff858f1c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8059070a-a973-530d-8d9b-0e4cb14d5b65","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4ea345d9-fe7e-558f-b710-2bb252185ef8","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"bb3e11cb-517f-5331-9de9-039d796fed2d"}},"staticQueryHashes":["3666801979"]}